초록 ▼

The present invention comprises a composition comprising a matrix (12) adapted to be placed in drug- and permeation-enhancing mixture-transmitting relation to a selected skin (18) or other body site. The matrix (12) contains sufficient amounts of drug, permeation enhancer(s) and poly-N-vinyl amide t

The present invention comprises a composition comprising a matrix (12) adapted to be placed in drug- and permeation-enhancing mixture-transmitting relation to a selected skin (18) or other body site. The matrix (12) contains sufficient amounts of drug, permeation enhancer(s) and poly-N-vinyl amide to continuously administer to the site, the drug, in a therapeutically effective amount, and the permeation-enhancing mixture, in an amount effective to enhance the permeation of the skin (18) to the drug, the device (10) shows increased transdermal flux as compared to the transdermal flux of the drug from a device (10) containing no poly-N-vinyl amide. Incorporating poly-N-vinyl amide into the transdermal system also improves the adhesion and stability of the system.

대표청구항 ▼

[ What is claimed is:] [1.]1. A method for enhancing the transdermal flux of a drug from a transdermal device comprising:(a) incorporating into a reservoir of a transdermal 5-25 wt % poly-N-vinyl-2-pyrrolidone, wherein said device comprises:(i) a reservoir containing an estrogen and a progestin and

[ What is claimed is:] [1.]1. A method for enhancing the transdermal flux of a drug from a transdermal device comprising:(a) incorporating into a reservoir of a transdermal 5-25 wt % poly-N-vinyl-2-pyrrolidone, wherein said device comprises:(i) a reservoir containing an estrogen and a progestin and a permeation enhancing amount of a monoglyceride or a mixture of monoglycerides of a fatty acid with a total monoesters content of at least 51% or a lactic ester of an alcohol, separately or in combination, said estrogen, progestin, and permeation enhancer being dispersed and/or dissolved in a polymeric carrier;(ii) a backing layer adjacent the skin distal surface of the device;(iii) means for maintaining the reservoir in drug and permeation enhancer transmitting relation with the skin; and(b) placing the device onto the skin of a person. [2.]2. A method for enhancing adhesion of a transdermal device comprising:(a) incorporating into a reservoir of a transdermal 5-25 wt % poly-N-vinyl-2-pyrrolidone, wherein said device comprises:(i) a reservoir containing an estrogen and a progestin and a permeation enhancing amount of a monoglyceride or a mixture of monoglycerides of a fatty acid with a total monoesters content of at least 51% or a lactic ester of an alcohol, separately or in combination, said estrogen, progestin, and permeation enhancer being dispersed and/or dissolved in a polymeric carrier;(ii) a backing layer adjacent the skin distal surface of the device;(iii) means for maintaining the reservoir in drug and permeation enhancer transmitting relation with the skin; and(b) placing the device onto the skin of a person. [3.]3. A method for enhancing the stability of a transdermal device comprising:(a) incorporating into a reservoir of a transdermal 5-25 wt % poly-N-vinyl-2-pyrrolidone, wherein said device comprises:(i) a reservoir containing an estrogen and a progestin and a permeation enhancing amount of a monoglyceride or a mixture of monoglycerides of a fatty acid with a total monoesters content of at least 51% or a lactic ester of an alcohol, separately or in combination, said estrogen, progestin, and permeation enhancer being dispersed and/or dissolved in a polymeric carrier;(ii) a backing layer adjacent the skin distal surface of the device; and(iii) means for maintaining the reservoir in drug and permeation enhancer transmitting relation with the skin.